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Intravenous vortioxetine to accelerate onset of effect in 
major depressive disorder: a 7-day randomized, double-blind, 
placebo-controlled exploratory study
Elmars Rancansa, Janos Zamborib, Mads Dalsgaardb, Corine Baayenb,  
Johan Arebergb, Anders Ettrupb and Ioana Floreab 
This 7-day randomized, double-blind, placebo-controlled 
fixed-dose study (NCT03766867) explored the potential 
for accelerating the onset of antidepressant efficacy 
of single-dose intravenous (IV) vortioxetine at oral 
vortioxetine treatment initiation. Patients (ages 18–
65 years) hospitalized per standard-of-care with major 
depressive disorder, who were currently treated with 
a selective serotonin reuptake inhibitor or serotonin-
norepinephrine reuptake inhibitor for a major depressive 
episode [Montgomery–Åsberg Depression Rating 
Scale (MADRS) total score ≥ 30], received one dose of 
single-blind IV placebo (1-day placebo lead-in period) 
before being randomly switched to either single-dose 
IV vortioxetine 25 mg plus daily oral vortioxetine 10 mg 
(n = 39), or IV placebo plus daily oral placebo (n = 41). In 
the placebo lead-in period, patients improved slightly by 
0.6 MADRS-6 point; however, at day 1 after randomization, 
both treatment groups had improved by approximately 
3 MADRS-6 points (mean difference = −0.8; P = 0.263), 
the study thus not meeting its primary endpoint. Similar 
results were seen for other outcomes except a numerically 
larger improvement in anxiety symptoms with vortioxetine 
vs placebo. Pharmacokinetic data confirmed that IV 
vortioxetine facilitated reaching steady-state plasma 
concentration within 24 h. IV plus oral vortioxetine was well 
tolerated, with low levels of nausea as the most common 
adverse event. Int Clin Psychopharmacol 35: 305–312 
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Introduction
Major depressive disorder (MDD) is a disabling illness 
with symptoms spanning across emotional, cognitive 
and physical domains, and with a substantial negative 
impact on patients’ daily functioning and quality of life 
(American Psychiatric Association, 2016). The immedi-
ate goal of antidepressant treatment is to resolve acute 
emotional symptoms and obtain symptomatic remission. 
However, long-term treatment aims broader at achieving 
sustained functional recovery and help patients return 
to their usual family, psychosocial, and work functioning 
(Malhi and Mann, 2018).
There is evidence that the duration of the depressive 
episode is critical for treatment outcomes and long-term 
prognosis (Kraus et al., 2019). In addition to early and 
effective intervention, fast onset of therapeutic action 
may facilitate symptomatic relief at an early illness stage 
and shorten the time during which patients are emotion-
ally distressed, potentially at risk of suicide, and function-
ally impaired.
While most of the currently available treatments may 
require several weeks to induce clinically relevant symp-
tomatic improvement (Machado-Vieira et al., 2008), a 
number of new compounds with fast-acting properties are 
being developed, including the recently approved adjunc-
tive intranasal esketamine for treatment-resistant depres-
sion (Popova et al., 2019) and intravenous (IV) brexanolone 
for postpartum depression (Meltzer-Brody et al., 2018), and 
oral SAGE-217 for major depression in phase II develop-
ment (Gunduz-Bruce et al., 2019). However, these gluta-
matergic/GABAergic agents have significant side effects, 
primarily dissociation and sedation, and esketamine and 
brexanolone are available only through a Risk Evaluation 
and Mitigation Strategies (REMS) program. Consequently, 
a medical need remains for rapid-acting treatments with 
long-term efficacy and tolerability for broad MDD.
Vortioxetine is an efficacious antidepressant with a favora-
ble risk–benefit profile (Katona et al., 2012; Thase et al., 
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2016; Baldwin et al., 2016a; Citrome, 2016) and potential 
for fast onset based on mechanism of action (Bétry et al., 
2013). Specifically, 5-HT
1A
 receptor agonism with vorti-
oxetine may lead to rapid desensitizing of autoreceptors 
in the raphe nucleus (Bétry et al., 2013), and 5-HT
3
 recep-
tor antagonism may reduce GABAergic input from hip-
pocampal interneurons, which in turn may increase the 
serotonin-mediated activation of glutamatergic neurons 
in the frontal cortex (Dale et al., 2018). Thereby, vortioxe-
tine may counteract the initial suppression of 5-HT neu-
rotransmission following inhibition of the SERT, which is 
thought to account for the 2-to 3-week delay in the onset 
of effect typically seen with selective serotonin reuptake 
inhibitors (SSRIs) (Bétry et al., 2013; Artigas et al., 2018).
While the steady-state plasma concentration level with 
oral vortioxetine is reached after approximately 2 weeks 
(Areberg et al., 2012), an initial, single IV dose of 17 mg 
added to oral vortioxetine 10 mg/day has been demon-
strated to facilitate a rapid increase (within 24 h) of vor-
tioxetine exposure to the steady-state level (Vieta et al., 
2019). In this previous study, however, no separation of 
17 mg IV vortioxetine and 10 mg/day oral vortioxetine 
from IV placebo plus oral vortioxetine was seen at day 
7 in the primary endpoint, the mean change from base-
line in Montgomery–Åsberg Depression Rating Scale 
(MADRS) total score. The aim of the current study was 
to explore the early onset of efficacy and the safety and 
tolerability within the first week of treatment, of a single 
initial, IV dose of 25 mg vortioxetine added to 10 mg daily 
oral vortioxetine, using a study design aiming at mitigat-
ing potential limitations in the previous IV study.
Methods
Patients and study design
This multisite, parallel-group, fixed-dose study included 
patients aged 18–65 years with a DSM-5 diagnosis of 
recurrent MDD and a current major depressive episode 
(MDE; classification code 296.3x), who were admitted 
to hospital per clinical practice. Patients had to have 
had the current MDE for at least 3 months and less than 
12 months, and experience severe depressive symptoms 
MADRS total score ≥30 at screening and at baseline] 
after one trial of SSRI/serotonin-norepinephrine reup-
take inhibitor (SNRI) monotherapy (citalopram, escit-
alopram, paroxetine, duloxetine, venlafaxine, sertraline) 
at approved dose, for at least 6 weeks. Patients with 
any psychiatric comorbidity as assessed using the Mini 
International Neuropsychiatric Interview (Sheehan et 
al., 1998) – including alcohol or other substance abuse/
dependence – or with a history of mania, hypomania, or 
any psychotic disorder, were excluded, as were patients 
who were pregnant or at the risk of suicide.
Eligible patients were randomly switched with a ratio of 
1:1 directly, without a washout period, from current SSRI/
SNRI to double-blind treatment with either a single 
dose of IV vortioxetine 25 mg (250 ml saline infused over 
2 hours) followed by 1 week of daily oral vortioxetine 
10 mg (vortioxetine group), or to a single initial dose of IV 
placebo saline infusion followed by 1 week of daily oral 
placebo (placebo group). Patients were hospitalized per 
clinical practice throughout the 1-week treatment period, 
with a safety follow-up approximately 4 weeks after the 
end of treatment. To minimize the placebo response 
induced by the IV procedure during the randomized 
treatment period, all eligible patients received a sin-
gle-blind IV placebo infusion followed by a placebo tab-
let on the day before randomization. An internal, blinded 
safety evaluation was conducted after randomization of 
the first eight patients before continuing the study. A 
safety follow-up was conducted approximately 1 month 
after completion of the randomized treatment period.
The IV dose of 25 mg vortioxetine was selected based 
on a pharmacokinetic model evaluating plasma expo-
sure with a 25 mg IV dose combined with an oral dose 
of 10 mg/day (recommended starting dose). The pharma-
cokinetic model predicted that this regimen within 24 h 
would be comparable to steady-state levels of 15 mg/day 
oral vortioxetine dosing.
The study was conducted between December 2018 and 
July 2019 at 13 sites in Bulgaria, Estonia, and Latvia. 
The study protocol was approved by the independent 
ethics committee of each study site. The study was con-
ducted in accordance with the International Conference 
on Harmonization Good Clinical Practices guidelines 
and with the ethical principles of the Declaration of 
Helsinki. The trial is registered at ClinicalTrials.gov 
(NCT03766867).
Assessments
Efficacy data were collected at day 0 (baseline), and at 
days 1, 3, and 7, except for the patient-reported Patient 
Global Impression of Change (PGI-C, see below), which 
was assessed daily from days 1 through 7; safety data in 
addition on day 1 (i.e., in the placebo lead-in) and at 2 h 
after the IV infusion (given in the morning of day 0). 
Pharmacokinetic samples were collected at 2 h, at bed-
time and at 24 h post-IV infusion, and at day 7 (sampling 
time unspecified).
Depressive symptom severity was rated independently 
and blindly by clinicians using the MADRS (Montgomery 
and Åsberg, 1979), modified to assess symptoms within 
the past 24 h at each visit. The primary efficacy scale 
was the six-item MADRS-6 subscale score (possible 
score range 0–36), calculated as the sum of the follow-
ing items: Apparent sadness, reported sadness, inner ten-
sion, lassitude, inability to feel, and pessimistic thoughts 
(item numbers 1, 2, 3, 7, 8, and 9). Developed to obtain 
a more unidimensional measure of the core symptoms of 
depression compared with the full scale, the MADRS-6 
subscale has shown sensitivity to detect treatment effects 
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and early improvement with antidepressant treatment 
(Bech et al., 2002; Bech, 2006; Thase et al., 2012; Vieta 
et al., 2019). The total score (possible score range 0–60) 
was calculated as the sum of scores on the 10 items of 
the full MADRS. Higher MADRS scores indicate worse 
symptom severity.
Illness severity and improvement was recorded by cli-
nicians using the Clinical Global Impressions – Severity 
of Illness (CGI-S) and CGI – Improvement (CGI-I; not 
assessed at randomization baseline) (Guy, 1976). Both 
scales range from 1 to 7, with higher CGI scores indicat-
ing worse status/worsening of illness, a CGI-I score of 4 
reflecting neither improvement nor worsening relative 
to baseline. A patient-version of the CGI, the PGI-C 
(Hurst and Bolton, 2004), was used to record patient-re-
ported improvement in overall illness status relative to 
a baseline, with higher scores indicating larger improve-
ment and a score of 1 indicating no change. In addition, 
patient-reported symptoms of depression and anxiety 
were assessed using the Hospital Anxiety and Depression 
Scale subscales for depression (HADS-D) and anxiety 
(HADS-A) (Zigmond and Snaith, 1983). Scores for each 
of the 7-item subscales (possible range 0-21) were calcu-
lated as the sum of item scores, higher scores indicating 
worse symptom severity.
Safety and tolerability assessments included adverse 
events, vital signs, clinical safety laboratory tests, electro-
cardiograms (ECGs), and physical examinations.
Statistical analyses
Safety analyses comprised all patients who received the 
IV infusion or took at least one tablet in the randomized 
period (treated patients). Treatment-emergent adverse 
events (TEAEs) were summarized using descriptive 
statistics. Efficacy analyses comprised all randomized 
patients who received the IV infusion and took at least 
one tablet, and who had valid MADRS-6 subscale score 
assessments at baseline and at least once postbaseline 
[full-analysis set (FAS)].
The primary efficacy endpoint assessing the change from 
baseline at day 1 in the MADRS-6 subscale score was ana-
lyzed using a restricted maximum likelihood-based mixed 
model for repeated measurements (MMRM), including 
study site, visit, and treatment as fixed effects, baseline 
MADRS-6 subscale score as a covariate, and interactions 
for treatment-by-visit and baseline MADRS-6 subscale 
score-by-visit.
P values for the treatment differences were estimated 
based on the least squares mean for the treatment-by-
visit interaction in the MMRM. Other endpoints were 
analyzed using MMRM models similar to that specified 
for the primary endpoint.
To account for multiplicity, a hierarchical testing proce-
dure was applied, testing first the mean treatment differ-
ence for the primary endpoint (the change from baseline 
to day 1 in MADRS-6 subscale score), then for the key 
secondary endpoint (change from baseline to day 3 in 
MADRS-6 subscale score), provided the primary end-
point met statistical significance at a threshold of 0.05. 
If not, testing according to the strategy was stopped, and 
subsequent P values considered nominal.
Mean changes from baseline and mean treatment dif-
ferences with standard errors (SEs) are reported, unless 
otherwise stated. All statistical tests are two-sided. Data 
were analyzed using SAS, Version 9.4 statistical software.
Sample size determination
Assuming an effect size at day 1 of 3 MADRS-6 points, no 
missing data, and a standard deviation (SD) of 4.5, a total 
of 80 patients (40 per treatment group) would provide a 
power of at least 80% at a two-sided alpha level of 5%.
Population pharmacokinetic analysis
The sampled plasma concentrations of vortioxetine were 
analyzed and modeled using non-linear mixed effect 
methods, based on a previously developed model for 
vortioxetine (Areberg et al., 2014). The population phar-
macokinetic model was used to simulate full individual 
plasma concentration-time profiles.
Results
All 81 patients who were screened entered the placebo 
lead-in, and 80 (98.8%) were randomized to the dou-
ble-blind treatment period (Fig. 1). Of those randomized, 
78 patients (97.5%) completed the study.
The mean age was 47 years and most (73%) patients were 
females; the mean MADRS total score at baseline was 
35, indicating severe depression (Table 1). The treatment 
groups were comparable in demographic and clinical 
characteristics.
Efficacy
Improvement during the single-blind lead-in was −0.6 
MADRS-6 point; at day 1 after the IV infusion with either 
vortioxetine or placebo, improvements were seen of −3.6 
(SE = 0.6) and −2.8 (SE = 0.6) MADRS-6 points for vorti-
oxetine and placebo, respectively, with a nonsignificant 
difference of −0.8 (SE = 0.7, P = 0.263) in favor of vorti-
oxetine (Fig. 2a). As the primary endpoint was not met, 
testing according to the strategy was stopped, and subse-
quent P values considered nominal. The corresponding 
changes from baseline in MADRS total score were −4.8 
(SE = 0.8) for vortioxetine and −4.2 (SE = 0.8) for placebo 
(P = 0.514; Fig.  2b). Similar results were seen at days 3 
and 7, with a slightly larger numerical improvement in 
the placebo group at the end of treatment (Fig. 2).
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Other endpoints showed comparable results (Table 2) 
except the HADS-A subscale score, for which numer-
ically larger improvements were seen with vortiox-
etine than with placebo, most pronouncedly at the 
earlier timepoints [mean difference vs placebo = −1.3 
(P = 0.064) and −1.4 (P = 0.063) at days 1 and 3, respec-
tively (Table 2)].
Pharmacokinetics
Plasma concentrations were within the lower expected 
range based on simulations (see Supplementary Fig., 
Supplemental digital content 1, http://links.lww.com/ICP/
A78 which shows the estimated vs prior expected vor-
tioxetine plasma concentration), and steady-state was 
reached within 24 h after dosing.
Safety
In the placebo lead-in, a total of five patients (6.2%) 
reported an adverse event. In the randomized treatment 
period, adverse events were reported by 21 patients 
(53.8%) treated with vortioxetine and 15 (36.6%) treated 
with placebo (Table 3); the overall most common TEAEs 
(≥10% in either group) were nausea, dizziness, and ery-
thema. More patients treated with vortioxetine reported 
erythema, insomnia, anxiety, and increased blood pres-
sure, whereas events of sedation and somnolence were 
more common among those receiving placebo. Two 
patients, both in the vortioxetine group, reported mild 
infusion site skin reactions.
More patients in the placebo group reported nausea [7 
(17.1%) vs 5 (12.8%) in the vortioxetine group]. Most of 
the patients (four of five) in the vortioxetine group who 
reported nausea did so within 24 h postinfusion, with 
no new incidences after day 3, whereas in the placebo 
group, nausea occurred relatively later, with five of seven 
patients reporting nausea on day 2 or later. Nausea was 
mostly mild (four of six events for vortioxetine and four 
of seven for placebo) and otherwise of moderate inten-
sity. One patient in the vortioxetine group reported vom-
iting of mild intensity. The median duration of nausea 
within the 7-day treatment period was 3 days among 
patients treated with vortioxetine, and 1 day among those 
receiving placebo.
One patient allocated to placebo reported a serious 
adverse event (exacerbation of MDD) 15 days after first 
dose (safety follow-up period). No deaths occurred dur-
ing the study, and no patients withdrew due to adverse 
events. There were no notable findings in the clinical 
safety laboratory tests, vital signs, or ECG parameters.
Discussion
Although this small-scale, exploratory study confirmed 
previous findings that a single initial dose of vortioxetine 
facilitated plasma-concentration at the steady-state level 
within 24 h after dosing (Vieta et al., 2019), no difference 
vs placebo was seen in the early antidepressant effect 
Fig. 1
Patient disposition.
Table 1 Demographic and baseline clinical characteristics
Vortioxetine (n = 39) Placebo (n = 41)
Demographic and clinical characteristics
Women, n (%) 28 (71.8) 30 (73.2)
Age (years) 47.3 (11.0) 46.9 (13.7)
Ethnicity, n (%)
 Caucasian 39 (100) 40 (97.6)
 Black or African-American 0 1 (2.4)
BMI (kg/m2) 25.0 (3.7) 24.6 (3.5)
Duration of current episode (days) 150.6 (50.2) 165.5 (77.1)
 Median (days) 140 131
Number of previous episodes 3.4 (2.0) 2.8 (1.7)
 Range 1-10 1-8
Treatment at study entry
 SSRI, n (%) 26 (66.7) 29 (70.7)
 SNRI, n (%) 13 (23.3) 12 (29.3)
Baseline clinical assessments
MADRS total score 35.6 (3.4) 34.7 (2.7)
MADRS-6 subscale score 23.4 (2.3) 22.9 (2.2)
CGI-S score 5.1 (0.6) 5.1 (0.5)
HADS-D score 16.5 (3.2) 15.7 (3.2)
HADS-A score 12.1 (3.0) 11.8 (3.6 )
PGIC score 1.4 (0.6) 1.5 (0.6)
Mean (SD) reported unless otherwise specified. Demographic and clinical char-
acteristics based on all treated patients; clinical assessments based on the 
full-analysis set. 
CGI-I, Clinical Global Impressions – Improvement; CGI-S, Hospital Anxiety and 
Depression Scale – Depression; HADS-A, Hospital Anxiety and Depression 
Scale – Anxiety; MADRS, Montgomery–Åsberg Depression Scale; PGI-C, 
patient global impression of change; SNRI, serotonin-norepinephrine reuptake 
inhibitors; SSRI, selective serotonin reuptake inhibitors.
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of a single initial IV dose of vortioxetine added to oral 
daily treatment at any timepoint during a 7-day treat-
ment period. Thus, the study did not meet its primary 
endpoint.
Albeit statistically nonsignificant, the numerically larger 
improvement in patient-rated symptoms of anxiety 
(HADS-A) among patients treated with vortioxetine 
compared with placebo is consistent with an early anx-
iolytic effect of vortioxetine seen in previous studies 
showing reduced levels of anxiety in anxious depres-
sion (Alvarez et al., 2012; Baldwin et al., 2016b) as well as 
generalized anxiety (Bidzan et al., 2012; Liebowitz et al., 
2017). In contrast, transient anxiogenic effects are seen 
in some patients after the initial administration of SSRIs, 
potentially due to 5-HT
1A
-mediated reductions in sero-
tonergic firing (Piñeyro and Blier, 1999; Zienowicz et al., 
2006; Akimova et al., 2009). In this study, the numerical 
reductions in symptoms of anxiety with vortioxetine vs 
placebo were most pronounced at earlier timepoints, con-
sistent with the findings from the previous study with IV 
vortioxetine (Vieta et al., 2019). Such early improvements 
in anxiety symptoms with vortioxetine may hypotheti-
cally be related to modulation of serotonin receptors in 
addition to SERT blockade, specifically 5-HT
1A
 agonism 
leading to desensitization of autoreceptors and increased 
serotonergic neurotransmission (Bétry et al., 2013).
In the previous exploratory study of the efficacy of a 
single IV infusion of vortioxetine compared with IV pla-
cebo, in which both treatments were followed by daily 
oral vortioxetine, all patients improved fast and substan-
tially (at approximately 14 points in MADRS total score 
at day 7), with no separation between the treatments 
Fig. 2
MADRS-6 subscale score (a) and MADRS total score (b) across study period (FAS, MMRM). Treatment differences are based on the least 
squares mean; error bars represent standard errors. FAS, full-analysis set; MADRS, Montgomery–Åsberg Depression Scale; MMRM, mixed model 
for repeated measurements.
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for the primary endpoint at day 7; however, numerically 
larger improvements with IV vortioxetine at days 1 and 
3 were seen consistently across outcomes (Vieta et al., 
2019). Based on these findings, the current study design 
applied features aiming at mitigating limitations related 
to assay sensitivity in the previous IV study, foremost 
the high response rate among patients who received IV 
placebo plus oral vortioxetine. Thus, the current study 
used a placebo-only (IV and oral) comparator, hence 
omitting any effects from oral vortioxetine in the placebo 
arm, and counteracting expectation bias by reducing the 
probability of receiving active treatment. Likewise, the 
single-blind placebo lead-in in this study aimed at reduc-
ing the impact from expectation bias by masking the 
time when patients could potentially receive active treat-
ment. Finally, patients in this study were required to be 
hospitalized per standard of care to reduce improvement 
caused by per-protocol hospital care and environment.
Keeping in mind the study design differences between 
this and the previous IV study and the consequent lim-
itations in their direct comparison, overall, the response 
in the placebo arm in this study was smaller compared to 
Vieta et al. (2019) (−4.2 vs −5.9 MADRS total score points 
at day 1) and the lead-in period may thus have had some 
impact in attenuating the placebo response, as may the 
blinding of raters to patients’ previous status. However, 
the response in the vortioxetine arm in this study was 
also smaller, resulting in a net effect of comparable mag-
nitude to that observed by Vieta et al. (2019).
This study confirmed the favorable tolerability profile 
that has previously been shown with vortioxetine, also 
as a switch therapy (Baldwin et al., 2016a; Thase et al., 
2017). In this study, switching patients directly and rap-
idly from an SSRI/SNRI to a single high dose of vortiox-
etine did not compromise tolerability, with lower levels 
of nausea compared both with the previous examination 
of 17 mg IV vortioxetine in a nonswitch population (Vieta 
et al., 2019) and with oral doses of vortioxetine (5–20 mg) 
(Baldwin et al., 2016a), likely reflecting tolerance to the 
side effects elicited by SERT inhibition developed with 
the previous SSRI/SNRI therapy.
Table 2 Efficacy endpoints (full-analysis set, mixed model for repeated measurements)
Mean (SE) change from baseline Mean (SE) difference vs placebo P value
Day 1
 MADRS-6 subscale score −3.6 (0.6) −0.8 (0.7) 0.263
 MADRS total score −4.8 (0.8) −0.6 (0.9) 0.514
 CGI-S score −0.3 (0.1) 0.1 (0.1) 0.624
 CGI-I scorea 3.3 (0.1) −0.1 (0.2) 0.759
 HADS-D subscale score −2.6 (0.6) 0.1 (0.7) 0.874
 HADS-A subscale score −3.4 (0.5) −1.3 (0.7) 0.064
 PGI-C scorea 2.9 (0.3) −0.2 (0.3) 0.465
Day 3
 MADRS-6 subscale score −5.3 (0.8) −0.1 (1.0) 0.956
 MADRS total score −7.5 (1.0) 0.3 (1.3) 0.798
 CGI-S score −0.7 (0.1)  0.0 (0.2) 0.944
 CGI-I scorea 3.1 (0.1) −0.0 (0.2) 0.830
 HADS-D subscale score −3.6 (0.7) 0.2 (0.9) 0.864
 HADS-A subscale score −4.1 (0.6) −1.4 (0.7) 0.063
 PGI-C scorea  3.2 (0.3) −0.3 (0.3) 0.353
Day 7
 MADRS-6 subscale score −6.5 (0.9) 0.8 (1.2) 0.542
 MADRS total score −9.4 (1.3) 1.2 (1.7) 0.461
 CGI-S score −0.9 (0.2) 0.1 (0.2) 0.563
 CGI-I scorea 2.8 (0.2) −0.1 (0.2) 0.749
 HADS-D subscale score −5.1 (0.8) 0.8 (1.1) 0.464
 HADS-A subscale score −4.4 (0.6) −0.5 (0.7) 0.518
 PGI-C scorea 3.8 (0.3) −0.2 (0.4) 0.545
Vortioxetine, n = 39; placebo, n = 41.
CGI-S, Clinical Global Impressions – Severity of Illness; CGI-I, Clinical Global Impressions – Improvement; FAS, full-analysis set; HADS-D, Hospital Anxiety and 
Depression Scale – Depression; HADS-A, Hospital Anxiety and Depression Scale – Anxiety; MADRS, Montgomery–Åsberg Depression Scale; MMRM, mixed model for 
repeated measurements; PGI-C, patient global impression of change.
aAbsolute score. Treatment differences are based on the least squares mean. 
Table 3 Summary of treatment-emergent adverse events and 
treatment-emergent adverse events occurring in ≥5% in either 
treatment group during the 1-week treatment period
Vortioxetine, n (%) Placebo, n (%)
Number of treated patients 39 41
Patients with TEAEs 21 (53.8) 15 (36.6)
TEAEs occurring in ≥5% in either group
Nauseaa 5 (12.8) 7 (17.1)
Dizziness 4 (10.3) 3 (7.3)
Erythema 4 (10.3) 0
Insomnia 3 (7.7) 1 (2.4)
Headache 2 (5.1) 1 (2.4)
Diarrhea 2 (5.1) 1 (2.4)
Anxiety 2 (5.1) 0
Blood pressure increased 2 (5.1) 0
Sedation 1 (2.6) 3 (7.3)
Somnolence 1 (2.6) 4 (9.8)
No serious adverse events or deaths occurred during the study. No patients with-
drew from the study due to adverse events. 
TEAE, treatment-emergent adverse event.
aOne patient in the vortioxetine group reported vomiting. 
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Limitations
The single-blind placebo lead-in may have succeeded 
only partly in reducing the placebo response, as indi-
cated by the limited improvement after the IV placebo 
infusion in the lead-in period relative to the substantial 
response seen after IV placebo in the randomized treat-
ment period. Because investigators were not blinded to 
the time of randomization, this might suggest that the 
clinician-rated assessments (MADRS; CGI scales) may 
have been subject to some level of bias related to their 
awareness of when improvements could be expected. 
Although the patients were blinded to the placebo lead-in 
study feature, a similar pattern was observed for the 
patient-reported assessments (HADS scales; PGI), which 
might hypothetically be explained by ‘socially transmit-
ted’ placebo effects (Chen et al., 2019), that is, investi-
gators’ inadvertent and subconscious communication of 
their own expectations to the patient, and/or by patients 
not expecting an effect immediately after the first (pla-
cebo-) IV based on their previous experience or knowl-
edge about antidepressant (SSRI) treatment. Altogether, 
such limitations may have led to reduced assay sensitiv-
ity, hence attenuating any treatment differences between 
vortioxetine and placebo, in this already small study.
Conclusion
This small-scale, exploratory study showed no difference 
in the early antidepressant effect of a single initial IV 
dose of vortioxetine added to daily oral treatment ver-
sus placebo at any timepoint during a 7-day treatment 
period. Except a numerically larger improvement in 
anxiety symptoms with vortioxetine vs placebo, similar 
results were seen for other endpoints. Pharmacokinetic 
data confirmed that IV vortioxetine facilitated reaching 
steady-state plasma concentration within 24 h. IV plus 
oral vortioxetine was well tolerated, with low levels of 
nausea as the most common adverse event, and no new 
safety signals compared to previous studies with vortiox-
etine administered as IV or oral formulations.
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